๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bangalore
Clinical trial register · India

Clinical Trials in Bangalore

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 332 Mumbai 259 Hyderabad 237 Bangalore 193 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca39 Eli Lilly and Company15 Novartis Pharmaceuticals11 Novo Nordisk A/S10 Janssen Research & Development, LLC9
Site location
New Delhi332 Mumbai259 Hyderabad237 Bangalore193 Pune189
All 274 locations
Target enrolment
to
193 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Active, closed
A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
NCT05456425Pterygium
Cloudbreak Therapeutics, LLC
Phase 3
660
Chandigarh, Ahmedabad, Bangalore, Bhubaneswar, Bikaner, Noida
2022-06-30
Active, closed
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116Psoriatic Arthritis
Sun Pharmaceutical Industries Limited
Phase 3
529
Surat, Belagavi, Hubli, Pune, Bangalore, Chennai, Secunderabad, Sevilla
2022-06-30
Active, closed
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
NCT05878691Advanced Solid Tumor, Lymphoma
Glenmark Specialty S.A.
Phase 1
320
Vijayawada, Visakhapatnam, Gurgaon, Bangalore, Bengaluru, Kannur, Aurangabad, Mumbai
2022-06-28
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
Celgene
Phase 3
939
Hyderabad, Bangalore, Ernฤkulam, Mumbai, Kolkata, Puducherry
2022-06-23
Active, closed
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512Breast Cancer
AstraZeneca
Phase 3
644
Bangalore, Jaipur, Kolkata, Nagpur, Nashik, New Delhi, Puducherry, Vadodara
2022-05-16
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
AstraZeneca
Phase 3
760
Ahmedabad, Bangalore, Delhi, Hyderabad, Jaipur, Kolkata, Mumbai, New Delhi
2022-03-28
Active, closed
COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events
NCT05333068Multivessel Coronary Artery Disease, Ischemia, Vulnerable Plaque, Coronary Artery Disease
Diagram B.V.
Not applicable
1,223
Ahmedabad, Bangalore, Chandigarh
2022-03-16
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
791
Ahmedabad, Bangalore, Delhi, Howrah, Hyderabad, Jaipur, Kolkata, Marg Jaipur
2022-02-18
Recruiting
Acetazolamide for Treatment Resistant Schizophrenia
NCT04887792Schizophrenia, Schizo Affective Disorder
Vishwajit Nimgaonkar, MD PhD
Phase 1/2
60
Bangalore
2022-02-01
Active, closed
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
NCT04919226Neuroendocrine Tumors
ITM Solucin GmbH
Phase 3
259
Bangalore, New Delhi, Mumbai
2021-12-21
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Bangalore, Chennai, Madurai, Mumbai, Nashik, New Delhi, Pune, Vijayawada
2021-12-10
Recruiting
A Planned Study at Multiple Sites is Being Done to Compare the Results of Two Types of Trifocal Toric Intraocular Lenses Used in Cataract Surgery
NCT07232615Presbyopia Correction, Astigmatism, Cataract
Biotech Healthcare Holding Gmbh
Not applicable
138
Bangalore, Chennai
2021-11-22
Recruiting
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
NCT04743765Hip Fractures, Myocardial Injury
Population Health Research Institute
Not applicable
1,100
Bangalore, Alappuzha, Trivandrum, New Delhi, Puducherry
2021-11-22
Active, closed
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
NCT05134441Multiple Sclerosis
Immunic AG
Phase 3
1,121
Bangalore, Mangalore, Nagpur, New Delhi, Pune, Shimla, Varanasi
2021-11-18
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
776
Bangalore, Gurugram, Kolkata, Mumbai, Nashik, New Delh, Pune, Thane
2021-11-17
Active, closed
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
454
Bangalore, Delhi, Hyderabad, Mumbai, Nashik
2021-10-28
Active, closed
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090Papillary Renal Cell Carcinoma
AstraZeneca
Phase 3
148
Bangalore, Belagavi, Jaipur, Mysore, Nashik
2021-10-28
Recruiting
A Prospective, Randomized Clinical Study of Two Phakic Toric Implantable Lenses
NCT06839898Myopia, Moderate, Myopic Astigmatism, Myopia, Degenerative
Biotech Healthcare Holding Gmbh
Not applicable
172
Bangalore
2021-10-10
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
874
Bangalore, Thiruvananthapuram, Mumbai, Nagpur, Nashik, Pune, Hyderabad
2021-10-04
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
Novartis Pharmaceuticals
Phase 3
448
Bangalore, New Delhi, Hyderabad
2021-09-20
By invitation
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
NCT04957719Acute Myocardial Infarction
Viatris Innovation GmbH
Phase 3
25,000
Ahmedabad, Aligarh, Aurangabad, Bangalore, Bathinda, Belagavi, Bhubaneswar, Bikaner
2021-08-14
Recruiting
European and North Indian Cohort of KaWasaki dIsease
NCT06305611Kawasaki Disease
Meyer Children's Hospital IRCCS
Observational
103
Bangalore, Chandigarh, Chennai, Kochi, Kolkata
2021-07-13
Active, closed
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca
Phase 3
893
Bangalore, Mohali, Mysuru, Nagpur, New Delhi, Vadodara, Varanasi
2021-05-10
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04873362Breast Cancer
Hoffmann-La Roche
Phase 3
1,188
Ahmedabad, Bangalore, Mumbai, Nashik, Pune, New Delhi, North WEST Delhi, Ratnagiri Kilminnal
2021-05-04
Active, closed
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715Breast Cancer; HER2-positive; Metastatic
AstraZeneca
Phase 3
1,157
Ahmedabad, Bangalore, Bengaluru, Calicut, Gurgaon, Mysuru, Nashik, New Delhi
2021-04-26
Rows per page Showing 126–150 of 193
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/bangalore

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.